Benefit and danger from immunotherapy in myasthenia gravis

Valentina Damato, Amelia Evoli, Carmelo Rodolico, Giulia Nicocia, Giovanni Antonini, Rocco Liguori

Research output: Contribution to journalArticle


In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
Original languageEnglish
Pages (from-to)1367-1375
Number of pages9
JournalNeurological Sciences
Publication statusPublished - 2021


  • Checkpoint inhibitors
  • Emerging therapy
  • Immunotherapy
  • Refractory myasthenia gravis


Dive into the research topics of 'Benefit and danger from immunotherapy in myasthenia gravis'. Together they form a unique fingerprint.

Cite this